GSK Raises 2025 Profit Forecast as HIV and Cancer Drugs Drive Growth
GSK boosts annual profit forecast to 12% growth as specialty medicines outperform. CEO Emma Walmsley's final report shows strong Q3 results despite US vaccine challenges.
/ 921 items
#Healthcare↓
BridgeBio's Encaleret Scores Major Win in Rare Calcium Disorder Trial
BridgeBio Pharma (BBIO) announces positive phase 3 results for encaleret in ADH1, showing 76% response rate. FDA filing planned for first half of 2026 alongside BBP-418 submission.
Akebia Therapeutics Halts Proposed Anemia Trial After FDA Feedback
Akebia Therapeutics will not start its planned trial for Vafseo anemia treatment in non-dialysis kidney disease patients after the FDA requested a larger, costlier study.
FDA Issues Major Warning to Philips Over Medical Device Quality Failures
The U.S. FDA sent a warning letter to Royal Philips (PHG) regarding critical manufacturing and quality system violations at three medical device facilities, leading to a 5% drop in stock value.
Stephens Initiates Overweight Coverage on Candel Therapeutics, Citing Transformative Pipeline and Limited Competition
Candel earned a $15 stock rating. Its key drug, CAN-2409, is seen as transformative because it improves current treatments.
Regeneron Beats Wall Street Estimates on Strong Dupixent and Libtayo Sales
Regeneron Pharmaceuticals exceeds Q3 2025 expectations with $3.75B revenue, driven by blockbuster eczema drug Dupixent and cancer treatment Libtayo, despite Eylea competition challenges.